FibroGen
After FDA snub, EMA backs FibroGen, Astellas’ roxadustat
Phil Taylor
Akebia Therapeutics, anaemia, Astellas, chronic kidney disease, daprodustat, EU, FibroGen, GlaxoSmithKline, Haematology, regulatory approval, roxadustat, vadadustat
0 Comment
FDA rejects FibroGen/AZ’s roxadustat, asking for new trial
Phil Taylor
AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat
0 Comment
FDA adcomm turns down FibroGen, AZ’s roxadustat for CKD anaemia
Phil Taylor
AstraZeneca, chronic kidney disease, daprodustat, fda, FibroGen, GlaxoSmithKline, nephrology, roxadustat
0 Comment
GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival
Richard Staines
anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin
0 Comment
AZ preps for US filing of kidney disease anaemia drug
Richard Staines
Astellas, AstraZeneca, chronic kidney disease, FibroGen
0 Comment
Astellas gets nod in Japan for roxadustat, ahead of GSK rival
Phil Taylor
Astellas, chronic kidney disease, daprodustat, FibroGen, GlaxoSmithKline, roxadustat
0 Comment
AstraZeneca shows cardiovascular safety for roxadustat
George Underwood
AstraZeneca, chronic kidney disease, FibroGen, kidney, roxadustat
0 Comment
Galapagos and FibroGen drugs offer hope in IPF
Richard Staines
Boehringer Ingelheim, FibroGen, Galapagos, idiopathic pulmonary fibrosis, respiratory, Roche
0 Comment
Drugs improve on existing medicines from Boehringer and Roche.